📈 Live Market Tracking
Every NSE and BSE corporate filing, read and explained by AI within minutes — impact, key figures, short/long-term view and what to watch.
Live · AI analyzer runs every 5 min (07:00–23:55 IST)
Latest filing: 2026-10-13 19:22
0 analysed today
FollowTelegram
0
Today
152,139
All-time analysed
43,645
Positive
6,747
Negative
92,898
Neutral
8,781
Watch
📊 Last 7 days — analysed filings by sentiment
Note: These are AI-generated, educational summaries of public NSE
filings — grounded in each document, but not investment advice and possibly incomplete.
Verify against the original filing and consult a SEBI-registered adviser before acting.
42 announcements match the current filters (relevance ≥ 5).
Krsnaa Diagnostics Allots 16.21 Lakh Warrants at ₹566/share to Promoters
Krsnaa Diagnostics has allotted 16,21,000 fully convertible warrants at an issue price of ₹566 each on a preferential basis to promoter and promoter group entities, representing a total issue size of ₹91.75 crore. The company has collected 25% upfront subscription money totaling ₹22.94 crore, with the remaining 75% payable upon conversion within 18 months. Upon full conversion, the promoter and promoter group stake will increase from 27.11% to 29.70%. The warrant issue price of ₹566 represents a modest premium of 6.3% over the current market price of ₹532.7.
Confidence: HIGH
What changedKrsnaa Diagnostics issued 16.21 lakh convertible warrants to promoters at ₹566 each, receiving ₹22.94 crore as 25% upfront subscription.
Why it mattersDemonstrates promoter capital commitment at a premium to market price and increases promoter holding towards 30%, while injecting up to ₹91.75 crore in equity capital over 18 months.
Total warrants allotted: 16,21,000Warrant issue price: ₹ 566/-Upfront amount received (25%): ₹ 22,93,71,500/-Total fundraise value: ₹91.75 croreTotal fundraise vs Market Cap: ~5.3%Post-conversion promoter stake: 29.70%
📅 Short termPositive sentiment driver as promoters infuse capital at ₹566, above the prevailing market price of ₹532.7, without immediate dilution of equity capital.
📈 Long termStrengthens the balance sheet and funds ongoing geographic expansions in Rajasthan and retail pathology, while consolidating promoter control from 27.11% to 29.70%.
⚠ Risk flags
- Minor equity dilution of ~4.8% on fully diluted share capital upon full conversion
- Warrant holders could forfeit the 25% upfront money if the stock trades significantly below ₹566 at the end of 18 months
Key Highlights
Allotment of 16,21,000 convertible warrants at ₹566 per warrant (total value of ₹91.75 crore)
Received 25% upfront subscription money aggregating to ₹22,93,71,500
Promoter shareholding to rise from 27.11% to 29.70% post full conversion
Warrant holders have an 18-month window from October 13, 2026, to pay the remaining 75% and convert
Warrant issue price of ₹566 is at a premium to the current market price of ₹532.7
👀 What to Watch
Track the deployment of the initial ₹22.94 crore proceeds into ongoing capex (such as Rajasthan and Maharashtra expansions) and watch for subsequent tranche conversions over the 18-month tenure.
BSE Approves Issuance of 16.21 Lakh Convertible Warrants at Rs 566 to Promoters
Krsnaa Diagnostics has received a corrected in-principle approval from BSE Limited for issuing 16,21,000 convertible warrants on a preferential basis to its Promoter and Promoter Group. The warrants are priced at Rs 566 each (convertible into equity shares of face value Rs 5 each), representing a total fundraising amount of approximately Rs 91.75 crore. This capital infusion accounts for roughly 5.3% of the company's current market cap of Rs 1,741 crore. The filing rectifies factual errors noted in BSE's earlier approval letter dated October 08, 2026.
Confidence: HIGH
What changedBSE issued a corrected in-principle approval letter rectifying factual errors from its prior approval dated October 08, 2026.
Why it mattersThe Rs 91.75 crore promoter infusion bolsters net worth, strengthens the balance sheet (current debt at Rs 531 crore), and signals promoter commitment to growth initiatives.
Convertible Warrants: 16,21,000Issue Price per Warrant: Rs 566Face Value per Share: Rs 5Total Fundraise vs Market Cap: ~5.3%
📅 Short termAdministrative clarity enables the company to proceed with preferential allotment formalities without regulatory hitches.
📈 Long termUpon full conversion, promoter holding will increase marginally from the current 27.11%, supporting ongoing retail and PPP expansion plans.
⚠ Risk flags
- Minor equity dilution of ~4.8% upon eventual conversion into equity shares
- Subscription and conversion timelines span up to 18 months
Key Highlights
Received corrected in-principle approval from BSE for 16,21,000 convertible warrants
Issue price set at Rs 566 per warrant convertible into equity shares of face value Rs 5
Total capital to be raised stands at approximately Rs 91.75 crore
Warrants allotted exclusively to Promoter and Promoter Group entities
👀 What to Watch
Track shareholder and final regulatory approvals, along with the timeline for allotment and upfront receipt of 25% warrant subscription money.
Krsnaa Diagnostics Secures In-Principle Approval for ₹91.75 Cr Promoter Warrant Issue at ₹566/Share
Krsnaa Diagnostics has received in-principle approval from NSE and BSE for the preferential issue of 16,21,000 convertible warrants to promoters at ₹566 per share, aggregating to approximately ₹91.75 crore. The issue price of ₹566 represents a ~6.4% premium over the current market price of ₹532.0. The total potential capital infusion of ₹91.75 crore represents roughly 5.3% of the company's current market cap of ₹1,730 crore and 9.2% of its net worth (₹992 crore). The approval is subject to customary listing conditions and compliance with SEBI insider trading and ICDR regulations.
Confidence: HIGH
What changedStock exchanges granted in-principle approval to issue 16.21 lakh preferential convertible warrants to the promoter group.
Why it mattersIncreases promoter skin in the game at a premium to the current market price while potentially injecting ₹91.75 crore in equity capital to support ongoing expansions.
Total warrants: 16,21,000Issue price per share: Rs. 566Face value: Rs. 5Total fundraise value: ~₹91.75 CrFundraise vs Market Cap: ~5.3%
📅 Short termPositive sentiment driver as promoters are infusing capital at ₹566, above the prevailing market price of ₹532.
📈 Long termStrengthens equity base and increases promoter holding (currently 27.11%), aiding funding for network expansion across Rajasthan and Maharashtra.
⚠ Risk flags
- Equity dilution of ~4.9% upon full warrant conversion
- Rectification of factual errors in BSE letter still pending
Key Highlights
In-principle approval received from NSE and BSE for 16,21,000 convertible warrants
Warrants convertible into equity shares of face value ₹5 each at an issue price of ₹566 per share
Total capital to be raised amounts to approximately ₹91.75 crore, entirely from the Promoter and Promoter Group
Issue price of ₹566 is at a premium to the current market price of ₹532
Company noted BSE approval letter contains factual errors requiring rectification, to be resubmitted separately
👀 What to Watch
Track the receipt of the rectified in-principle approval from BSE and subsequent board allotment timelines for the 18-month warrant conversion window.
Krsnaa Diagnostics Receives In-Principle Approval for ₹91.75 Cr Promoter Warrant Issue at ₹566/Share
Krsnaa Diagnostics has obtained in-principle approval from BSE and NSE for issuing 16,21,000 convertible warrants to its Promoter and Promoter Group on a preferential basis. The warrants are convertible into equity shares of face value ₹5 each at an issue price of ₹566 per warrant, representing a total fundraise of approximately ₹91.75 crore. The issue price of ₹566 reflects a premium of ~6.4% over the current market price of ₹532. The potential capital infusion equates to roughly 5.3% of Krsnaa's current market cap of ₹1,730 crore, which will bolster promoter commitment and support balance sheet liquidity.
Confidence: HIGH
What changedStock exchanges granted in-principle approval to execute the preferential allotment of 16,21,000 convertible warrants to promoters.
Why it mattersDemonstrates promoter skin in the game at a price above the prevailing market price and raises ₹91.75 crore of equity growth capital for ongoing expansions.
Warrants to be issued: 16,21,000Issue price per warrant: Rs. 566/-Face value: Rs. 5/-Total fundraise value: ₹91.75 CrFundraise vs Market Cap: ~5.3%
📅 Short termPositive sentiment driver as promoters commit capital at ₹566 per share vs current price of ₹532, although BSE's letter rectification is still pending.
📈 Long termIncreases promoter shareholding (currently 27.11%) upon conversion within 18 months, reinforcing alignment and easing net debt levels (currently ₹531 Cr).
⚠ Risk flags
- BSE approval letter contains factual errors requiring rectification
- Equity dilution of ~4.8% upon eventual conversion
Key Highlights
Received in-principle exchange approval for 16,21,000 convertible warrants
Issue price fixed at ₹566 per share/warrant, a premium to current price of ₹532
Total capital to be raised amounts to approximately ₹91.75 crore (~5.3% of market cap)
Convertible into 16,21,000 equity shares of face value ₹5 each
Allotted on a preferential basis exclusively to Promoter and Promoter Group
👀 What to Watch
Track the formal allotment of warrants, receipt of the upfront 25% subscription money, and subsequent filing of the rectified in-principle letter from BSE.
Krsnaa Diagnostics Approves Sale of Equipment for Up to ₹120 Crore to Transition Asset-Light
Krsnaa Diagnostics' Board has approved the sale of identified diagnostic equipment for an aggregate consideration of up to ₹120 crore. This asset monetization represents approximately 14.7% of its TTM revenue (₹816 crore) and 12.1% of its net worth (₹992 crore). The initiative aims to shift the company toward an asset-light, capital-efficient model and recycle capital toward core diagnostics and growth opportunities. The assets involved are unencumbered freehold items, and the company stated there will be no material adverse impact on operations or P&L.
Confidence: HIGH
What changedThe Board approved the monetization of unencumbered diagnostic equipment worth up to ₹120 crore to move toward an asset-light model.
Why it mattersUnlocking ₹120 crore can significantly improve liquidity, reduce debt (currently ₹531 crore), and enhance ROCE without impairing core testing operations.
Equipment sale limit: up to ₹120 croreSale value vs TTM revenue: ~14.7%Sale value vs Net worth: ~12.1%Sale value vs Total Debt: ~22.6%
📅 Short termPositive sentiment driver as the capital release improves liquidity and provides balance sheet flexibility.
📈 Long termSupports a structural shift toward a higher-ROCE, asset-light operating structure, enabling self-funded expansion into retail diagnostics.
⚠ Risk flags
- Execution risk regarding closure of deals with prospective buyers at expected valuations
- Potential operational dependency if equipment is leased back or third-party service arrangements change
Key Highlights
Approved equipment sale for aggregate consideration of up to ₹120 crore
Asset monetization represents ~14.7% of TTM revenue and ~6.9% of market cap (₹1,736 crore)
Assets sold are freehold and not subject to any security interest or lender encumbrances
Company targeting an asset-light model to enhance ROCE (currently 13.0%) without impacting operations
👀 What to Watch
Track the execution timeline, buyer details, and final realized consideration from the Operations Committee, as well as how proceeds are deployed (debt reduction vs. retail expansion).
Krsnaa Diagnostics Approves Preferential Issue of 16.21 Lakh Warrants to Promoters via Postal Ballot
Krsnaa Diagnostics shareholders have approved a Special Resolution via Postal Ballot for the issuance of up to 16,21,000 warrants convertible into equity shares on a preferential basis to the Promoter and Promoter Group. The remote e-voting concluded on September 17, 2026, with 92.69% of votes cast in favor and 7.31% against. The infusion will increase promoter stake from the current 27.11% level upon conversion, signaling promoter commitment. Key issue terms such as warrant pricing and total fundraise amount were not specified in this filing.
Confidence: HIGH
What changedShareholders officially passed the Special Resolution approving the preferential allotment of up to 16.21 lakh convertible warrants to the promoter group.
Why it mattersIncreases promoter skin-in-the-game from the existing 27.11% stake and provides fresh growth/equity capital to fund operations or capex.
Warrants to be issued: 16,21,000Face value per share: Rs.5/- eachApproval percentage (in favour): 92.6895%Cut-off date: August 14, 2026
📅 Short termNeutral to slightly positive sentiment as the resolution passed comfortably with >92% shareholder support, confirming promoter capital backing.
📈 Long termEquity dilution will be accompanied by promoter ownership expansion, strengthening capital base for retail footprint and PPP contract buildouts.
⚠ Risk flags
- Dilution to minority shareholders upon warrant conversion
- Issue price and valuation basis not stated in this voting disclosure
Key Highlights
Shareholders approved issuance of up to 16,21,000 convertible warrants to Promoters on a preferential basis
Special Resolution passed with 92.6895% votes in favor (1,73,06,571 votes)
Dissenting votes accounted for 7.3105% (13,64,985 votes) across 50 members
E-voting period ran from August 19, 2026, to September 17, 2026
👀 What to Watch
Track subsequent filings for the issue price, total funds raised, allotment timelines, and warrant exercise schedule.
Krsnaa Signs 15-Year Concession Agreement for 4 PET-CT Centers in Punjab
Krsnaa Diagnostics has signed a Concession Agreement with the Department of Health & Family Welfare, Government of Punjab, following its August 14, 2026 Letter of Award. The project entails developing, operating, and maintaining PET-CT diagnostic facilities at 4 selected Government Hospitals under a DBFOT (Design, Build, Finance, Operate, Maintain and Transfer) model. This marks Krsnaa's entry into the high-end PET-CT oncology diagnostics segment, structured on a cash-based user-fee model across a 15-year tenure. While total contract value was not disclosed upfront due to scan volume dependencies, it expands Krsnaa's diagnostic offerings beyond its existing 186 CT/MRI centers and 120 pathology labs.
Confidence: HIGH
What changedKrsnaa completed all formalities to execute the definitive 15-year Concession Agreement for 4 PET-CT centers in Punjab.
Why it mattersEnters a new high-value diagnostic segment (PET-CT/oncology) via a cash-based PPP model, securing a 15-year revenue stream while diversifying from traditional CT/MRI and pathology.
Number of hospital locations: 4Concession period: 15 yearsLetter of Award date: August 14, 2026Contract consideration: not disclosed
📅 Short termNeutral to mildly positive sentiment as the agreement is formalized; market will look for capex requirements and rollout timelines.
📈 Long termStrengthens long-term revenue visibility via a multi-year cash-collection PPP model, providing entry into oncology diagnostics without working-capital stretch common to reimbursement tenders.
⚠ Risk flags
🔬 Flagged for deeper Multibagger analysis — view briefs →
- DBFOT capex execution risk and equipment procurement dependency
- Volume-dependent revenue realization (no guaranteed minimum scan volume disclosed)
Key Highlights
Executed Concession Agreement for PET-CT Diagnostic Facilities at 4 Government Hospitals in Punjab
Project awarded for a Concession Period of 15 years on a DBFOT Public-Private Partnership (PPP) basis
Follows initial Letter of Award received on August 14, 2026
Order size not disclosed upfront as revenues are based on actual scan volumes and user charges under a cash model
👀 What to Watch
Track the capital expenditure outlay required for the 4 PET-CT setups and monitor the operational commissioning timeline across Punjab hospitals over upcoming quarters.
Krsnaa Diagnostics Faces Aggregate Disputed Tax Demand of ₹62.69 Cr Across 7 Assessment Years
Krsnaa Diagnostics has received appellate orders from CIT(Appeals), Pune under Section 250 of the Income-tax Act, 1961 for Assessment Years 2017-18 through 2023-24. The orders reflect an aggregate disputed demand of ₹62.69 Cr, with appeals dismissed for four years (AY18 to AY21) and partly allowed for three years (AY22 to AY24). The disputed demand represents approximately 64% of the company's TTM PAT of ₹98 Cr and 6.3% of its net worth (₹992 Cr). The company intends to appeal against these orders before the Income Tax Appellate Tribunal (ITAT).
Confidence: HIGH
What changedCIT(Appeals) Pune dismissed or only partly allowed appeals filed by Krsnaa Diagnostics across seven assessment years, upholding tax demands totaling ₹62.69 Cr.
Why it mattersThe ₹62.69 Cr demand is significant relative to annual profitability (~64% of TTM PAT of ₹98 Cr); an adverse outcome or mandatory deposit requirements could strain liquidity.
Aggregate disputed demand: ₹62,69,17,435Disputed demand vs TTM PAT: ~64%Disputed demand vs Net worth: ~6.3%Assessment years involved: AY 2017-18 to AY 2023-24
📅 Short termMay create negative sentiment around potential tax liabilities and cash outflows if pre-deposit amounts are mandated during ITAT appeal filings.
📈 Long termTax litigation before ITAT often takes extended periods; the ultimate outcome will determine whether provisions or write-offs are required.
⚠ Risk flags
- Adverse tax dispute outcome
- Potential requirement to pre-deposit 20% of disputed tax demand before ITAT stay
- Material impact on cash flow relative to TTM PAT
Key Highlights
CIT(Appeals) issued orders across 7 assessment years: AY 2017-18 through AY 2023-24
Total aggregate disputed tax demand stands at ₹62,69,17,435 (~₹62.69 Cr)
Four appeals dismissed (AY18-AY21 totaling ~₹22.08 Cr) and three partly allowed (AY22-AY24 totaling ~₹40.61 Cr)
For AY 2022-23, order dated Aug 28, 2026 reflected ₹19.63 Cr, while subsequent rectification reflected ₹31.73 Cr payable
Company plans to file further appeals before the ITAT based on legal and factual grounds
👀 What to Watch
Track the timeline of filings and stay applications before the ITAT, and watch for any provisioning or contingent liability disclosures in the upcoming quarterly financial results.
Krsnaa Diagnostics: Corrigendum on 16.21 Lakh Promoter Warrants; Stake to Rise to 29.70%
Krsnaa Diagnostics issued a corrigendum to its Postal Ballot Notice following directives from the NSE regarding its proposed preferential issue of share warrants. Under the proposal, 16,21,000 warrants will be allotted to promoter entities, including Mr. Rajendra Khivraj Mutha (75,000) and Krsna Diagnostics (Mumbai) Pvt Ltd (15,46,000). Upon full warrant exercise and ESOP dilution, the promoter and promoter group holding will increase from 27.11% to 29.70% across an expanded base of 3,50,65,279 shares. The e-voting process for shareholder approval is open until September 17, 2026.
Confidence: HIGH
What changedProvided expanded disclosures on promoter allottees, beneficial ownership, and post-issue capital structure per NSE review.
Why it mattersIncreases promoter commitment and equity ownership from 27.11% to 29.70%, injecting fresh equity capital into the company.
Warrants proposed: 16,21,000Pre-issue promoter holding: 27.11%Post-issue promoter holding: 29.70%Post-issue share count (fully diluted): 3,50,65,279E-voting end date: September 17, 2026
📅 Short termEnsures regulatory compliance ahead of the postal ballot closure on September 17, 2026, with minimal short-term price impact.
📈 Long termStrengthens capital structure and aligns promoter incentives through higher equity ownership without triggering open offer obligations.
⚠ Risk flags
- Minor equity dilution of non-promoter shareholding from 72.89% to 70.30%.
Key Highlights
Proposed preferential issue of 16,21,000 share warrants to promoter group entities.
Promoter holding set to increase from 27.11% (87,95,605 shares) to 29.70% (1,04,16,605 shares) on a fully diluted basis.
Allotment split: 75,000 warrants to Mr. Rajendra Khivraj Mutha and 15,46,000 warrants to Krsna Diagnostics (Mumbai) Private Limited.
Remote e-voting window closes at 5:00 PM IST on September 17, 2026.
👀 What to Watch
Track the shareholder voting results on September 17, 2026, and watch for final regulatory approvals and warrant exercise pricing details.
Krsnaa Diagnostics receives additional Income Tax demand of ₹12.10 Cr for AY 2022-23
Krsnaa Diagnostics received a rectification order under Section 154 read with Section 143(3) of the Income Tax Act, 1961 for AY 2022-23 from the ACIT, Pune. The order recomputes tax under Section 115BBE, raising the total balance payable from ₹19.63 Cr to ₹31.73 Cr, creating an additional demand of ₹12.10 Cr (~12.3% of TTM PAT). Total assessed income remains unchanged at ₹98.27 Cr. The company plans to file an appeal and rectification against the additional demand, having already contested the original assessment.
Confidence: HIGH
What changedIncome Tax Department issued a rectification order increasing the tax demand for AY 2022-23 by ₹12.10 Cr due to the application of Section 115BBE tax rates.
Why it mattersThe revised total demand of ₹31.73 Cr represents ~32.4% of TTM PAT (₹98 Cr), posing a potential financial liability if appellate proceedings are unfavorable.
Additional tax demand: ₹12,09,98,110Revised total tax payable: ₹31,73,28,734Total assessed income: ₹98,27,29,935Additional demand vs TTM PAT: ~12.3%Total revised demand vs TTM PAT: ~32.4%
📅 Short termNegative sentiment due to the unexpected tax liability; however, an appeal will defer immediate cash outflows pending appellate review.
📈 Long termLimited operational impact, though adverse resolution could lead to cash outflow and write-offs impacting net profit.
⚠ Risk flags
- Adverse tax dispute outcome leading to cash outflow of up to ₹31.73 Cr
- Potential for interest/penalty accruals pending final appellate resolution
Key Highlights
Additional tax demand of ₹12,09,98,110/- raised for Assessment Year 2022-23
Revised balance tax payable stands at ₹31,73,28,734/- vs ₹19,63,30,624/- earlier
Total assessed income remains unchanged at ₹98,27,29,935/-
Tax rate rectified to 60% plus 25% surcharge under Section 115BBE on additions under Sections 69A and 69C
Company is in the process of filing an appeal/rectification against the order
👀 What to Watch
Track the outcomes of the appeal filed before the appellate authority and any potential cash flow impact or tax provisioning in upcoming quarterly results.
Krsnaa Diagnostics to raise ₹91.75 Cr via preferential issue of warrants at ₹566/share
Krsnaa Diagnostics has announced the terms of a preferential issue of up to 16,21,000 convertible warrants at an issue price of ₹566 per warrant, aggregating to ₹91.75 crore. The warrants are proposed to be allotted to Mr. Rajendra Mutha (75,000 warrants for ₹4.25 crore) and Krsnaa Diagnostics (Mumbai) Private Limited (15,46,000 warrants for ₹87.50 crore). Each warrant is convertible into one equity share within an 18-month period. The total fundraise represents approximately 5.2% of the company's market capitalisation (₹1,757 crore) and comes at a premium to the current market price of ₹540.30.
Confidence: HIGH
What changedFormal disclosure of preferential warrant allotment terms, issue price (₹566), and investor allocation totaling ₹91.75 crore.
Why it mattersDemonstrates promoter capital commitment at a premium to current market price, infusing growth capital and strengthening the balance sheet.
Total fundraise amount: Rs. 91,74,86,000Fundraise vs Market cap: ~5.2%Issue price per warrant: INR 566Total warrants: 16,21,000Conversion window: 18 months
📅 Short termPositive sentiment likely due to insider participation at an issue price above the current market price of ₹540.30.
📈 Long termProvides equity funding to support ongoing PPP projects and retail expansion without increasing long-term debt leverage.
⚠ Risk flags
- Dilution to minority shareholders upon full conversion
- Dependency on full warrant conversion within 18 months for complete cash inflow
Key Highlights
Preferential issuance of up to 16,21,000 warrants aggregating to ₹91.75 crore.
Issue price fixed at ₹566 per warrant in accordance with SEBI ICDR Regulations as of August 18, 2026.
Krsnaa Diagnostics (Mumbai) Pvt Ltd to subscribe to 15,46,000 warrants, increasing stake from 2.36% to 6.78%.
Mr. Rajendra Mutha to subscribe to 75,000 warrants (post-allotment shareholding will be 23.79%).
Warrants have a conversion tenure of up to 18 months from allotment.
👀 What to Watch
Track shareholder/EGM approval outcome, receipt of the initial 25% warrant subscription amount, and clarity on end-use of proceeds towards capex/debt reduction in upcoming quarterly briefings.
Krsnaa Diagnostics seeks shareholder nod for Rs 91.75 Cr warrant issue to promoters at Rs 566/share
Krsnaa Diagnostics has issued a postal ballot notice seeking shareholder approval to issue up to 16,21,000 convertible warrants on a preferential basis to its Promoter and Promoter Group. The warrants are priced at Rs 566 per share (face value Rs 5 + Rs 561 premium), raising up to Rs 91.75 Cr, which represents ~5.1% of its current market cap of Rs 1,792 Cr. The issue price is slightly above the current market price of Rs 551. Remote e-voting is scheduled from August 19, 2026, to September 17, 2026.
Confidence: HIGH
What changedThe company formally initiated postal ballot proceedings to approve a preferential issue of 16.21 lakh convertible warrants to the promoter group at Rs 566 per warrant.
Why it mattersDemonstrates promoter commitment by injecting up to Rs 91.75 Cr in equity capital at a price above prevailing market rates, potentially raising promoter holding from the current 27.11% and supporting ongoing PPP expansion capex.
Total fundraise value: Rs 91,74,86,000Warrants offered: 16,21,000Issue price per warrant: Rs 566Fundraise vs Market cap: ~5.1%E-voting cut-off date: August 14, 2026
📅 Short termLikely to support market sentiment in the near term as promoters are infusing capital at Rs 566 per share, above current trading levels.
📈 Long termProvides long-term equity capital to strengthen the balance sheet (current debt Rs 531 Cr) and support expansion into new state PPP contracts and retail diagnostics.
⚠ Risk flags
- Equity dilution of ~4.8% on fully diluted equity base upon warrant conversion
- Warrant funds are received in tranches (25% upfront, 75% over up to 18 months)
Key Highlights
Preferential issuance of up to 16,21,000 convertible warrants to Promoter and Promoter Group
Issue price fixed at Rs 566 per warrant (Rs 5 face value plus Rs 561 premium)
Total fundraising size of up to Rs 91.75 Cr (~5.1% of market cap)
Remote e-voting window open from August 19, 2026 to September 17, 2026
👀 What to Watch
Track shareholder voting results after September 17, 2026, followed by stock exchange in-principle approvals and receipt of the mandatory upfront 25% warrant subscription amount.
22% Revenue Growth in Q1 FY27; Retail Segment Surges 64% YoY to Rs 19.3 Cr
Krsnaa Diagnostics reported a 22% YoY revenue growth to Rs 235.5 Cr for Q1 FY27, driven by the ramp-up of the Rajasthan contract and strong retail performance. However, PAT declined 19% YoY to Rs 16.6 Cr, and EBITDA margins contracted by 221 bps to 25% due to upfront fixed costs in Rajasthan. The retail segment showed significant momentum, with its revenue contribution rising to 8% of the total, up from 1% in the previous year. The company maintains a robust order book with over 200 CT/MRI centers planned for completion.
Confidence: HIGH
What changedThe company is transitioning from a purely PPP-driven model to a hybrid model with an increasing retail footprint (8% of revenue) and is currently absorbing high upfront costs for its Rajasthan expansion.
Why it mattersWhile top-line growth remains strong, the temporary margin compression and PAT decline reflect the execution risks of large-scale government contracts. The shift toward retail is critical for long-term margin stability and reducing receivable risks.
Q1 FY27 Revenue: Rs 235.5 CrQ1 Revenue vs TTM Revenue: 30.4%Retail Revenue Growth: 64%EBITDA Margin: 25%Q1 FY27 PAT: Rs 16.6 Cr
📅 Short termThe stock may face pressure due to the 19% YoY decline in PAT and margin contraction, despite healthy revenue growth.
📈 Long termThe structural shift toward a 20% retail revenue target by FY27 and the scale-up of the Rajasthan contract are positive long-term drivers if margins normalize.
⚠ Risk flags
- Margin compression from upfront expansion costs
- Stretched receivables from government entities
- High client concentration in government health departments
Key Highlights
Revenue from operations grew 22% YoY to Rs 235.5 Cr in Q1 FY27.
Retail revenue surged 64% YoY to Rs 19.3 Cr, now contributing 8% of total revenue.
PAT decreased 19% YoY to Rs 16.6 Cr from Rs 20.5 Cr in the year-ago period.
EBITDA margins compressed to 25% from 27% due to upfront costs for Rajasthan laboratories.
Radiology network expanded to 191 CT/MRI centers with a total of 120 accreditations (NABL + NABH).
👀 What to Watch
Monitor the utilization levels and margin recovery in the Rajasthan project over the next two quarters. Watch for the company's ability to maintain retail growth momentum and improve cash conversion from government contracts.
22% Revenue Growth in Q1 FY27; Rajasthan Project Goes Live; Promoter Warrant Issue Approved
Krsnaa Diagnostics reported a 22% YoY revenue growth to ₹235.5 Cr for Q1 FY27, primarily driven by the operationalization of the Rajasthan pathology network. The Rajasthan project contributed ₹25.7 Cr (approx. 11% of quarterly revenue) with 1,321 units now operational. However, PAT declined 19% YoY to ₹16.6 Cr as EBITDA margins contracted from 27% to 25% due to upfront fixed costs of new infrastructure. The Board also approved a preferential warrant issue to promoters, signaling internal backing as the company scales its retail and PPP segments.
Confidence: HIGH
What changedThe massive Rajasthan pathology contract has transitioned from the implementation phase to active operations, and the company has initiated a fundraise from promoters via share warrants.
Why it mattersRajasthan is a critical growth engine for Krsnaa; its successful scale-up is vital for hitting FY27 targets. The promoter warrant issue provides capital for expansion while signaling management's commitment despite recent margin pressure.
Q1 Revenue: ₹235.5 CrRajasthan Revenue Contribution: ₹25.7 CrQ1 Revenue vs TTM Revenue: 30.5%Retail Revenue Growth: 64% YoYEBITDA Margin: 25%
📅 Short termThe stock may face pressure due to the YoY decline in PAT and margin contraction, though the strong top-line growth and Rajasthan operationalization provide a fundamental floor.
📈 Long termThe structural expansion into Rajasthan and the growth of the high-margin retail segment (targeting 20% of revenue by FY27) could significantly re-rate the business as fixed costs are absorbed by higher volumes.
⚠ Risk flags
🔬 Flagged for deeper Multibagger analysis — view briefs →
- Margin compression due to high upfront fixed costs
- Dilution risk from the upcoming preferential warrant issue
- High dependency on government (PPP) contracts and associated receivable risks
Key Highlights
Revenue from operations increased 22% YoY to ₹235.5 Cr, with like-for-like projects growing 12%.
Rajasthan pathology network is now live with 31 mother labs, 62 hub labs, and 1,228 collection centers.
Retail segment revenue grew 64% YoY to ₹19.3 Cr, now reaching over 4,250 touchpoints.
PAT decreased to ₹16.6 Cr from ₹20.5 Cr YoY, reflecting a margin drop to 7% from 11%.
Secured a new project award in Himachal Pradesh for the installation of 34 CT scanners.
👀 What to Watch
Monitor the utilization ramp-up in the Rajasthan and Maharashtra projects over the next two quarters to see if operating leverage restores PAT margins to the 10-12% range. Investors should also watch for the specific pricing and size of the promoter warrant issue once detailed terms are disclosed.
Krsnaa Q1 Revenue up 22% to ₹235.5 Cr; Promoter to Infuse Capital via Warrants at ₹565
Krsnaa Diagnostics reported a 22% YoY revenue growth in Q1 FY27 to ₹235.53 Cr, driven by its expanding PPP footprint. However, Net Profit (PAT) declined by 19.3% YoY to ₹16.55 Cr, impacted by higher finance costs and hospital fees. The board approved a preferential issuance of 16.21 lakh warrants to promoters at ₹565 per share (a premium to the current market price), potentially raising ~₹91.6 Cr. A significant monitorable remains the ₹62.69 Cr income tax demand currently under appeal, which represents over 60% of the company's TTM PAT.
Confidence: HIGH
What changedThe company reported its Q1 FY27 financial results and announced a fresh capital infusion from promoters via warrants at a premium to the current market price.
Why it mattersThe revenue growth confirms the company's ability to win and execute large government tenders, but the PAT decline and tax litigation highlight operational and regulatory risks.
Q1 Revenue: ₹235.53 CrQ1 PAT: ₹16.55 CrWarrant Issue Price: ₹565Tax Demand vs TTM PAT: 61.6%Dividend per share: ₹2.00
📅 Short termThe stock may face pressure due to the YoY decline in PAT and the large tax demand, though the promoter warrant pricing at ₹565 may provide a psychological floor.
📈 Long termLong-term value depends on the company's ability to transition its revenue mix toward 20% retail by FY27 and resolve stretched receivables in states like Himachal Pradesh and Karnataka.
⚠ Risk flags
- Material income tax demand of ₹62.69 Cr
- Stretched receivables from government health departments
- Margin compression in the current quarter
Key Highlights
Revenue from operations increased 22% YoY to ₹235.53 Cr in Q1 FY27.
Net Profit (PAT) fell to ₹16.55 Cr from ₹20.52 Cr in the same quarter last year.
Promoter warrant issuance of 16.21 lakh units at a minimum price of ₹565, representing a ~5.1% value of current market cap.
Income tax demand of ₹62.69 Cr is being contested; ₹3.93 Cr deposited under protest.
Final dividend of ₹2.00 per share confirmed with a record date of September 18, 2026.
👀 What to Watch
Monitor the scale-up of the Rajasthan and Maharashtra contracts to see if margins recover from the current 24.6% level. Investors should also track the progress of the income tax appeals as the demand is material relative to annual profits.
KRSNAA Q1 Revenue Up 22% to ₹235.5 Cr; Board Approves ₹91.6 Cr Warrant Issue to Promoters
Krsnaa Diagnostics reported a 22% YoY increase in Q1 FY27 consolidated revenue to ₹235.53 Cr, though net profit declined to ₹16.55 Cr from ₹20.52 Cr due to higher finance and operational costs. The board approved a preferential issue of 16.21 lakh warrants to promoters at a minimum price of ₹565, signaling a potential capital infusion of ~₹91.6 Cr (approx. 5% of market cap). A final dividend of ₹2.00 per share was confirmed with a record date of September 18, 2026. Investors should note an ongoing income tax dispute involving a demand of ₹62.69 Cr, which the company is currently appealing.
Confidence: HIGH
What changedThe company has transitioned from FY26 results to Q1 FY27 reporting, initiated a promoter-led fundraise via warrants, and finalized the dividend timeline.
Why it mattersThe warrant issue provides growth capital and reinforces promoter commitment, while the mixed earnings reflect the challenge of maintaining margins amidst rising finance costs and government-linked receivables.
Q1 FY27 Revenue: ₹235.53 CrQ1 FY27 Net Profit: ₹16.55 CrWarrant Issue Value (est): ₹91.59 CrWarrant Issue vs Market Cap: ~5.1%Tax Demand under Appeal: ₹62.69 CrDividend per Share: ₹2.00
📅 Short termThe stock may face pressure due to the YoY profit decline, though the promoter warrant issue at ₹565 (near current market price) provides a psychological support level.
📈 Long termGrowth depends on scaling the retail segment from 8% to 20% of revenue and successfully operationalizing large PPP contracts in Rajasthan and Maharashtra.
⚠ Risk flags
- Significant income tax demand of ₹62.69 Cr
- Stretched receivables from government entities in Himachal Pradesh and Karnataka
- Rising finance costs impacting net margins
Key Highlights
Consolidated Revenue for Q1 FY27 rose 22.05% YoY to ₹235.53 Cr from ₹192.98 Cr
Net Profit for the quarter fell 19.3% YoY to ₹16.55 Cr, impacted by finance costs rising to ₹14.83 Cr
Preferential issue of 16,21,000 warrants to promoters at ₹565 or floor price, totaling ~₹91.6 Cr
Final dividend of ₹2.00 per share declared for FY25 with Record Date set for Sept 18, 2026
Income tax demand of ₹62.69 Cr under appeal; management views the demand as not tenable
👀 What to Watch
Monitor the conversion of warrants into equity over the next 18 months and the progress of the ₹62.69 Cr tax appeal, which represents ~6% of the company's net worth.
Q1 Revenue Up 22% to ₹235 Cr; Promoters to Inject Capital via 16.21 Lakh Warrants at ₹565
Krsnaa Diagnostics reported a strong 22% YoY revenue growth in Q1 FY27, reaching ₹235.5 cr, driven by its expanding PPP footprint. However, Net Profit declined 19% YoY to ₹16.55 cr, primarily due to finance costs doubling to ₹14.83 cr and increased depreciation. The board approved a preferential issuance of 16.21 lakh warrants to promoters at a minimum price of ₹565, representing a ~5% potential equity dilution. Additionally, the company is contesting a significant ₹62.69 cr income tax demand resulting from past search operations.
Confidence: HIGH
What changedThe company reported its Q1 FY27 financial performance and announced a promoter-led capital infusion through share warrants at a premium to the current market price.
Why it mattersWhile top-line growth remains robust due to government contracts, the bottom-line is under pressure from higher interest and depreciation costs. The promoter warrant subscription signals long-term confidence but will lead to equity dilution.
Revenue (Q1 FY27): ₹235.53 crPAT (Q1 FY27): ₹16.55 crWarrant Issue Price: ₹565Tax Demand Under Dispute: ₹62.69 crFinance Costs (Q1 FY27): ₹14.83 crWarrant Dilution (Approx): 5%
📅 Short termThe market may react cautiously to the PAT decline and the large tax demand, though the promoter warrant pricing at ₹565 provides a psychological floor.
📈 Long termStructural growth depends on the successful operationalization of large state-level contracts and the ability to scale the retail segment to 20% of revenue by FY27.
⚠ Risk flags
- Margin compression due to rising finance and depreciation costs
- Significant tax litigation risk (₹62.69 cr)
- Equity dilution from warrant conversion
- High receivables concentration in government segments
Key Highlights
Revenue from operations grew 22.1% YoY to ₹235.53 cr in Q1 FY27 from ₹192.98 cr.
Net Profit fell 19.3% YoY to ₹16.55 cr, with EPS dropping to ₹5.10 from ₹6.35.
Promoters to subscribe to 16.21 lakh warrants at ₹565 or higher, a premium to the current price of ₹556.8.
Income tax demand of ₹62.69 cr is under appeal; ₹3.93 cr already deposited under protest.
Final dividend of ₹2.00 per share for FY25 confirmed with a record date of September 18, 2026.
👀 What to Watch
Monitor the impact of rising finance costs on net margins and the progress of the ₹62.69 cr tax litigation. Investors should also track the utilization of the warrant proceeds for the planned expansion in Rajasthan and Maharashtra.
KRSNAA Q1 Revenue Up 22% to ₹235.5 Cr; Board Approves ₹91.6 Cr+ Promoter Warrant Issue
Krsnaa Diagnostics reported a mixed Q1 FY27 with revenue growing 22% YoY to ₹235.5 cr, driven by operationalizing new centers. However, Net Profit declined 19.3% YoY to ₹16.6 cr as operating expenses, particularly fees to hospitals (up 164% YoY), and finance costs rose significantly. The board approved a preferential issue of 16.21 lakh warrants to promoters at a minimum price of ₹565, representing a ~5% capital infusion relative to market cap. Additionally, the company is contesting a significant ₹62.7 cr income tax demand across multiple assessment years.
Confidence: HIGH
What changedThe company reported its Q1 FY27 results, announced a promoter-led fundraise via warrants, and provided a detailed update on pending tax litigation.
Why it mattersWhile revenue growth remains robust due to the PPP model expansion, the sharp decline in profitability and the large tax demand create near-term uncertainty. The promoter warrant issue at ₹565 (above current market price of ₹556.8) signals management confidence.
Revenue (Q1 FY27): ₹235.53 crNet Profit (Q1 FY27): ₹16.55 crTax Demand under Appeal: ₹62.69 crWarrant Issue Min. Price: ₹565Fees to Hospitals (Q1): ₹40.58 crTax Demand vs TTM PAT: ~61.4%
📅 Short termThe stock may face pressure due to the 19% profit decline and the quantification of the ₹62.7 cr tax demand, though the promoter warrant pricing may provide some support.
📈 Long termStructural growth depends on the successful transition to a higher retail revenue mix (target 20% by FY27) and resolving stretched receivables from government contracts.
⚠ Risk flags
- Significant tax litigation (₹62.69 cr)
- Margin compression due to rising hospital fees
- Stretched receivables from government entities
Key Highlights
Revenue from operations grew 22.1% YoY to ₹235.53 cr in Q1 FY27.
Net Profit fell 19.3% YoY to ₹16.55 cr compared to ₹20.52 cr in the year-ago quarter.
Board approved 16,21,000 share warrants to promoters at a minimum price of ₹565 per share.
Income tax demand of ₹62.69 cr is currently under appeal before tax authorities.
Final dividend of ₹2.00 per share confirmed with a record date of September 18, 2026.
👀 What to Watch
Monitor the impact of rising hospital fees on margins and the outcome of the ₹62.7 cr tax appeal, which represents over 60% of TTM PAT. Watch for the utilization of warrant proceeds for the planned Rajasthan and Maharashtra expansions.
KRSNAA Q1 Revenue Up 22% to ₹235.5 Cr; Promoters to Infuse Capital via 16.21 Lakh Warrants
Krsnaa Diagnostics reported a strong 22.1% YoY revenue growth in Q1 FY27, reaching ₹235.53 Cr, driven by its expanding PPP footprint. However, net profit declined by 19.3% YoY to ₹16.55 Cr, primarily due to a 135% surge in finance costs and a significant increase in fees paid to hospitals. The board approved a preferential issuance of 16.21 lakh warrants to promoters at a minimum price of ₹565, which is a premium to the current market price of ₹556.8. Additionally, the company is contesting a material income tax demand of ₹62.69 Cr, representing approximately 61% of its TTM net profit.
Confidence: HIGH
What changedThe company has transitioned into a higher-cost phase with increased debt servicing and hospital fees, while promoters have signaled confidence by committing to a warrant-based fundraise at a premium to the current price.
Why it mattersWhile top-line growth remains robust due to government contracts, the bottom-line pressure and tax litigation are significant near-term risks for a mid-cap healthcare player.
Q1 Revenue: ₹235.53 CrQ1 Net Profit: ₹16.55 CrTax Demand vs TTM PAT: 61.5%Warrant Floor Price: ₹565Finance Costs (Q1): ₹14.83 CrDividend per share: ₹2.00
📅 Short termThe stock may face pressure due to the profit decline and the disclosure of the large tax demand, though the promoter warrant pricing may provide some support.
📈 Long termLong-term value depends on the successful operationalization of the Rajasthan contract and the ability to scale the retail segment to 20% of revenue to offset PPP margin pressures.
⚠ Risk flags
- Material tax demand of ₹62.69 Cr
- Significant increase in finance costs (up 135% YoY)
- High receivables risk from government health departments
Key Highlights
Revenue from operations grew 22.1% YoY to ₹235.53 Cr from ₹192.98 Cr in the previous year's quarter.
Net profit for the quarter fell to ₹16.55 Cr vs ₹20.52 Cr YoY, impacted by finance costs rising to ₹14.83 Cr.
Preferential issue of 16.21 lakh warrants to promoters approved at a floor price of ₹565 per warrant.
Income tax demand of ₹62.69 Cr (₹626.90 million) currently under appeal before tax authorities.
Final dividend of ₹2.00 per share confirmed with a record date of September 18, 2026.
👀 What to Watch
Monitor the impact of rising operational costs (hospital fees) on margins and track the legal outcome of the ₹62.69 Cr tax demand, which is a significant contingent liability.
KRSNAA expands Himachal footprint with 34 CT Scan centers under new 7-year PPP agreement
Krsnaa Diagnostics has significantly scaled its operations in Himachal Pradesh, increasing its scope from 12 to 34 CT Scan centers under a new Public Private Partnership (PPP) agreement. The contract is for an initial 7-year term, extendable by 3 years, and will operate on a majority cash basis. This expansion adds 22 new centers to the company's existing radiology network of 186 CT/MRI centers, representing a ~12% increase in total radiology capacity. The shift to a 'cash basis' model is particularly notable given the company's historical challenges with stretched government receivables in this state.
Confidence: HIGH
What changedKrsnaa has transitioned from a 12-center arrangement to a much larger 34-center long-term contract in Himachal Pradesh, nearly tripling its presence in the state.
Why it mattersHimachal Pradesh is a key revenue contributor where receivables were previously stretched; scaling up on a cash basis secures long-term revenue visibility while potentially improving the company's working capital cycle.
New Center Count: 34Incremental Centers: 22Contract Tenure: 7 yearsCapacity Increase (vs 186 existing): ~11.8%TTM Revenue: ₹773 Cr
📅 Short termThe announcement is likely to be viewed positively by the market as it demonstrates contract stickiness and significant scale-up in a core geography.
📈 Long termThis provides a decade of revenue visibility for the radiology segment and validates the company's ability to renew and expand government tenders despite operational challenges.
⚠ Risk flags
🔬 Flagged for deeper Multibagger analysis — view briefs →
- Execution risks in hilly terrain
- Historical stretched receivables from government entities
- Dependency on global OEMs for equipment maintenance
Key Highlights
Scope of CT Scan diagnostic facilities increased from 12 to 34 Government Health Institutions in Himachal Pradesh
Agreement signed for an initial period of 7 years, with a 3-year extension option
Project to be implemented on a majority cash basis to improve liquidity
Represents a ~12% increase in the company's total CT/MRI center count (currently 186)
Contract renewal and scale-up reinforces Krsnaa's dominant position in the Indian PPP diagnostic segment
👀 What to Watch
Investors should monitor the execution timeline for the 22 additional centers and observe if the 'cash basis' clause effectively reduces the days sales outstanding (DSO) for the Himachal Pradesh cluster in upcoming quarterly results.
